Key result
Coxsackievirus A22 was detected 20 times in 16 patients between 2013-2020, including recurrent infections in an immunocompromised patient, yielding the first two near-complete European sequences.
Why the study?
There is limited information on the prevalence of Coxsackievirus A22 in patients as well as limited available genomic data.
Observational (n=16)
No
Next-generation sequencing complements conventional Sanger sequencing to characterize highly diverse enterovirus genotypes like CVA22, which can cause recurrent infections in immunocompromised patients.
BACKGROUND: Enteroviruses are highly diverse with a wide spectrum of genotypes and clinical manifestations. Coxsackievirus A22 (CVA22) has been detected globally from sewage surveillance; however, currently there is limited information on its prevalence in patients, as well as available genomic data. OBJECTIVE: We aimed to provide genomic and relative frequency data on CVA22 from a regional hospital perspective between 2013-2020. STUDY DESIGN: Sanger sequencing was performed on all samples with a positive enterovirus RT-qPCR result (≤Ct 32). Viral targeted sequence capture (ViroCap) and next-generation sequencing (NGS) (Illumina NextSeq 500) was used to characterize and generate near-complete CVA22 genomes for enteroviruses without genotyping results from Sanger sequencing. Epidemiological and phylogenetic analysis was performed using maximum likelihood trees on MEGA-11. RESULTS: A total of twenty detections derived from fecal material from sixteen patients were observed between 2013- 2020. One transplant recipient had five different CVA22 infection episodes over five years, with phylogenetic analysis indicating possible reinfection with an additional prolonged infection (>3 weeks). Furthermore, we report the first two near-complete CVA22 sequences from Europe, which grouped with a strain previously isolated from Bangladesh in 1999. CONCLUSIONS: We show a highly diverse enterovirus genotype which causes infections annually, typically in autumn and winter, and is capable of recurrent infection in an immunocompromised patient. Furthermore, we highlight the use of NGS to complement conventional targeted Sanger sequencing.
No takes yet. Share an insight, caveat, or question.
Cassidy et al. (2022) conducted an observational in Coxsackievirus A22 (CVA22) infection (n=16). Coxsackievirus A22 (CVA22) infection was evaluated on Detection and genomic characterization of CVA22. Coxsackievirus A22 was detected 20 times in 16 patients between 2013-2020, including recurrent infections in an immunocompromised patient, yielding the first two near-complete European sequences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: